Tigermed Consulting Co., Ltd
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to providing professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates: 33 subsidiaries 53 offices across China and 10 overseas offices in Hong Kong (China), Taiwan (China), USA, Canada, Korea, Australia, Japan, Malaysia, Singapore, and India over 1800 full-time staffs. Tigermed has set up international standard SOPs and serviced 300+ local and global clients in the conduct of 400+ clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 50 innovative drugs.
Locations
- APAC
- Australia
- Europe
- North America
Therapeutic Areas
- Bone / Osteoporosis
- Cardiovascular
- CNS
- Dental and Oral Health
- Dermatology
- Diabetes
- Endocrinology
- Gastroenterology
- Genetic Diseases
- Hematology
- Hepatology
- Immunology
- Infectious Diseases
- Inflammation
- Internal Diseases
- Metabolic Diseases
- Musculoskeletal
- Nephrology
- Neurology
- Nutrition and Health
- Obstetrics / Gynecology
- Oncology
- Ophthalmology
- Orthopedics
- Otolaryngology/ENT (Ear/Nose/Throat)
- Pediatrics / Neonatology
- Pharmacology / Toxicology
- Podiatry
- Psychiatry
- Pulmonary
- Respiratory
- Rheumatology
- Sleep
- Surgery
- Thrombosis
- Urology
- Vaccines